Industry Biotechnology
This indicator may be signaling that ERAS's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or exploring call options. A.I.dvisor backtested 97 similar cases where ERAS's Momentum Indicator exceeded 0, and of them led to a successful outcome. Odds of Success:
The Aroon Indicator for ERAS entered a downward trend on October 05, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 212 similar instances where the Aroon Indicator formed such a pattern. In 195 of the 212 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ERAS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
ERAS broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ERAS's RSI Indicator exited the oversold zone, 31 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Momentum Indicator moved above the 0 level on October 07, 2026. You may want to consider a long position or call options on ERAS as a result. In 81 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for ERAS just turned positive on October 02, 2026. Looking at past instances where ERAS's MACD turned positive, the stock continued to rise in 47 of 56 cases over the following month. The odds of a continued upward trend are 84%.
Following a +13.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where ERAS advanced for three days, in 212 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ERAS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.661) is normal, around the industry mean (26.823). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.